Agile Therapeutics Inc. (AGRX) Shares Down 3.7%
Agile Therapeutics Inc. (NASDAQ:AGRX) shares dropped 3.7% during trading on Tuesday . The company traded as low as $7.18 and last traded at $7.27, with a volume of 135,869 shares trading hands. The stock had previously closed at $7.55.
AGRX has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 target price on shares of Agile Therapeutics in a research note on Tuesday, May 10th. FBR & Co reissued a “buy” rating and issued a $17.00 target price on shares of Agile Therapeutics in a research note on Tuesday, May 10th. Zacks Investment Research lowered shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 29th. Finally, Noble Financial restated a “buy” rating and set a $15.00 price target on shares of Agile Therapeutics in a research report on Friday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $15.00.
The stock’s market capitalization is $208.95 million. The firm has a 50 day moving average price of $7.59 and a 200-day moving average price of $6.77.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Monday, May 9th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.11. Equities research analysts predict that Agile Therapeutics Inc. will post ($1.12) EPS for the current year.
An institutional investor recently raised its position in Agile Therapeutics stock. EAM Investors LLC boosted its position in shares of Agile Therapeutics Inc. (NASDAQ:AGRX) by 0.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 137,018 shares of the specialty pharmaceutical company’s stock after buying an additional 540 shares during the period. EAM Investors LLC owned about 0.61% of Agile Therapeutics worth $1,337,000 at the end of the most recent quarter.
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.